NASDAQ:RYTM Rhythm Pharmaceuticals (RYTM) Stock Price, News & Analysis → Biggest hedge fund manager has huge warning for U.S. dollar (From Stansberry Research) (Ad) Free rytm Stock Alerts $39.14 +0.64 (+1.66%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$38.14▼$39.6050-Day Range$38.01▼$43.8852-Week Range$15.50▼$52.57Volume371,714 shsAverage Volume554,760 shsMarket Capitalization$2.39 billionP/E RatioN/ADividend YieldN/APrice Target$54.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Rhythm Pharmaceuticals alerts: Email Address Rhythm Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside38.8% Upside$54.33 Price TargetShort InterestBearish17.37% of Shares Sold ShortDividend StrengthN/ASustainability-1.80Upright™ Environmental ScoreNews Sentiment0.12Based on 33 Articles This WeekInsider TradingSelling Shares$4.01 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.28) to ($1.98) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.18 out of 5 starsMedical Sector339th out of 921 stocksPharmaceutical Preparations Industry148th out of 428 stocks 3.4 Analyst's Opinion Consensus RatingRhythm Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageRhythm Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about Rhythm Pharmaceuticals' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted17.37% of the outstanding shares of Rhythm Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverRhythm Pharmaceuticals has a short interest ratio ("days to cover") of 17.5, which indicates bearish sentiment.Change versus previous monthShort interest in Rhythm Pharmaceuticals has recently increased by 3.82%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldRhythm Pharmaceuticals does not currently pay a dividend.Dividend GrowthRhythm Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRhythm Pharmaceuticals has received a 63.46% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Anti-obesity medication (A08)", "Clinical research services for deficiency diseases", and "Clinical research services for genetic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Rhythm Pharmaceuticals is -1.80. Previous Next 1.7 News and Social Media Coverage News SentimentRhythm Pharmaceuticals has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 33 news articles for Rhythm Pharmaceuticals this week, compared to 6 articles on an average week.Search InterestOnly 1 people have searched for RYTM on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Rhythm Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Rhythm Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,010,381.00 in company stock.Percentage Held by InsidersOnly 4.70% of the stock of Rhythm Pharmaceuticals is held by insiders.Read more about Rhythm Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Rhythm Pharmaceuticals are expected to grow in the coming year, from ($4.28) to ($1.98) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rhythm Pharmaceuticals is -12.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rhythm Pharmaceuticals is -12.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRhythm Pharmaceuticals has a P/B Ratio of 13.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Rhythm Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchBiggest hedge fund manager has huge warning for U.S. dollarPrescient CEO Makes Shocking New Prediction Known for his eerily accurate market calls over the years, this CEO has just revealed his newest prediction about "America's New Money."Get the details before it's taken offline. About Rhythm Pharmaceuticals Stock (NASDAQ:RYTM)Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Read More RYTM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RYTM Stock News HeadlinesMay 9, 2024 | msn.comMario Lemieux Foundation presents AHN with $5 million gift to establish Mario Lemieux Center for Heart Rhythm CareMay 9, 2024 | msn.comLeon Talks Transformative Portrayal of Blues Legend Eddie Taylor in ‘The Rhythm and the Blues’ | EUR ExclusiveMay 10, 2024 | Unstoppable Prosperity (Ad)“Crash Insurance” For Your RetirementWhen it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. May 9, 2024 | msn.comB of A Securities Downgrades Rhythm Pharmaceuticals (RYTM)May 9, 2024 | americanbankingnews.comNeedham & Company LLC Lowers Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target to $46.00May 8, 2024 | msn.comSpin Rhythm XD - Official VR & PlayStation Launch TrailerMay 8, 2024 | markets.businessinsider.comSteady Performance and Promising European Growth Justify Buy Rating for Rhythm PharmaceuticalsMay 8, 2024 | markets.businessinsider.comMaintaining Buy Rating on Rhythm Pharmaceuticals: Positive Outlook Amidst Growth and Upcoming CatalystsMay 10, 2024 | Unstoppable Prosperity (Ad)“Crash Insurance” For Your RetirementWhen it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. May 8, 2024 | finance.yahoo.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q1 2024 Earnings Call TranscriptMay 8, 2024 | finance.yahoo.comRhythm Pharmaceuticals Inc (RYTM) Q1 2024 Earnings Call Transcript Highlights: A Detailed ...May 8, 2024 | finance.yahoo.comQ1 2024 Rhythm Pharmaceuticals Inc Earnings CallMay 8, 2024 | americanbankingnews.comRhythm Pharmaceuticals (NASDAQ:RYTM) Shares Gap Down on Analyst DowngradeMay 7, 2024 | markets.businessinsider.comBuy Rating Affirmed: Rhythm Pharmaceuticals’ Growth and Clinical Advancements Fuel OptimismMay 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Rhythm Pharmaceuticals Amid Positive Prescription Growth and Pipeline PotentialMay 7, 2024 | msn.comRYTM Stock Earnings: Rhythm Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024May 7, 2024 | investorplace.comThe 3 Best Nasdaq Stocks to Buy in May 2024May 7, 2024 | msn.comMarvelle Healthcare Revolutionizes Hydration with the Debut of Premium Natural Mineral Water Brand, RhythmMay 7, 2024 | msn.comRhythm Pharmaceuticals GAAP EPS of -$2.35 misses by $0.33, revenue of $25.97M misses by $0.93MMay 7, 2024 | finance.yahoo.comRhythm Pharmaceuticals Reports Q1 2024 Results: Revenue Growth Amidst ChallengesMay 7, 2024 | globenewswire.comRhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business UpdateMay 6, 2024 | finance.yahoo.comRhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual MeetingMay 5, 2024 | americanbankingnews.comRhythm Pharmaceuticals (RYTM) Set to Announce Earnings on TuesdayMay 3, 2024 | msn.comAnMed Rhythm on the River in Powdersville postponed: Here's what you need to knowMay 2, 2024 | msn.comCelebrate dance with ‘Rhythm and Joy': A Kathak choreography by Shovana NarayanMay 2, 2024 | msn.comRhythm and Roots Festival's founder, Chuck Wentworth, passes away at 72May 2, 2024 | finance.yahoo.comCardiac Monitoring & Cardiac Rhythm Management Devices Market Worth $26.4 billion | MarketsandMarkets™See More Headlines Receive RYTM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rhythm Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today5/10/2024Next Earnings (Estimated)8/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RYTM CUSIPN/A CIK1649904 Webwww.rhythmtx.com Phone(857) 264-4280Fax857-264-4299Employees226Year FoundedN/APrice Target and Rating Average Stock Price Target$54.33 High Stock Price Target$79.00 Low Stock Price Target$42.00 Potential Upside/Downside+38.8%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($4.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-184,680,000.00 Net Margins-238.50% Pretax Margin-237.79% Return on Equity-96.02% Return on Assets-55.02% Debt Debt-to-Equity RatioN/A Current Ratio5.58 Quick Ratio5.43 Sales & Book Value Annual Sales$91.93 million Price / Sales25.96 Cash FlowN/A Price / Cash FlowN/A Book Value$2.87 per share Price / Book13.64Miscellaneous Outstanding Shares60,973,000Free Float58,107,000Market Cap$2.39 billion OptionableOptionable Beta1.94 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. David P. Meeker M.D. (Age 70)Chairman, President & CEO Comp: $1.17MMr. Hunter C. Smith M.B.A. (Age 55)CFO & Treasurer Comp: $692.2kMr. Joseph Shulman (Age 49)Chief Technical Officer Comp: $608.2kMr. Yann Mazabraud (Age 51)Executive VP & Head of International Comp: $747.43kMs. Jennifer Lee (Age 48)Executive VP & Head of North America Comp: $644.2kMr. Christopher German (Age 53)Corporate Controller, Principal Accounting Officer & Executive Director Mr. David ConnollyHead of Investor Relations & Corporate CommunicationsMr. Jim FlahertySenior VP & General CounselMs. Sarah RyanVice President of Sales & MarketingMs. Pamela J. Cramer (Age 50)Chief Human Resources Officer More ExecutivesKey CompetitorsAvidity BiosciencesNASDAQ:RNAPTC TherapeuticsNASDAQ:PTCTIndiviorNASDAQ:INDVVera TherapeuticsNASDAQ:VERAArvinasNASDAQ:ARVNView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 77,208 shares on 5/10/2024Ownership: 5.419%Lord Abbett & CO. LLCSold 2,361 shares on 5/9/2024Ownership: 0.461%ProShare Advisors LLCBought 1,527 shares on 5/8/2024Ownership: 0.023%Swiss National BankBought 3,600 shares on 5/7/2024Ownership: 0.153%Sei Investments Co.Bought 5,296 shares on 5/7/2024Ownership: 0.019%View All Insider TransactionsView All Institutional Transactions RYTM Stock Analysis - Frequently Asked Questions Should I buy or sell Rhythm Pharmaceuticals stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Rhythm Pharmaceuticals in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RYTM shares. View RYTM analyst ratings or view top-rated stocks. What is Rhythm Pharmaceuticals' stock price target for 2024? 6 equities research analysts have issued 12 month price objectives for Rhythm Pharmaceuticals' stock. Their RYTM share price targets range from $42.00 to $79.00. On average, they expect the company's share price to reach $54.33 in the next twelve months. This suggests a possible upside of 38.8% from the stock's current price. View analysts price targets for RYTM or view top-rated stocks among Wall Street analysts. How have RYTM shares performed in 2024? Rhythm Pharmaceuticals' stock was trading at $45.97 at the start of the year. Since then, RYTM shares have decreased by 14.9% and is now trading at $39.14. View the best growth stocks for 2024 here. When is Rhythm Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 6th 2024. View our RYTM earnings forecast. How were Rhythm Pharmaceuticals' earnings last quarter? Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) issued its quarterly earnings data on Tuesday, May, 7th. The company reported ($2.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.34) by $0.01. The company had revenue of $26 million for the quarter, compared to the consensus estimate of $26.90 million. Rhythm Pharmaceuticals had a negative net margin of 238.50% and a negative trailing twelve-month return on equity of 96.02%. The business's quarterly revenue was up 126.1% on a year-over-year basis. During the same period in the previous year, the business earned ($0.92) EPS. What ETFs hold Rhythm Pharmaceuticals' stock? ETFs with the largest weight of Rhythm Pharmaceuticals (NASDAQ:RYTM) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), ALPS Medical Breakthroughs ETF (SBIO), BlackRock Future Health ETF (BMED), SPDR S&P Biotech ETF (XBI), Harbor Corporate Culture Small Cap ETF (HAPS), Direxion Daily S&P Biotech Bull 3x Shares (LABU), iShares Micro-Cap ETF (IWC) and Principal Healthcare Innovators ETF (BTEC). What other stocks do shareholders of Rhythm Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Rhythm Pharmaceuticals investors own include VBI Vaccines (VBIV), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Viking Therapeutics (VKTX), Amarin (AMRN), Kadmon (KDMN), Pfizer (PFE), Sangamo Therapeutics (SGMO) and Sarepta Therapeutics (SRPT). When did Rhythm Pharmaceuticals IPO? Rhythm Pharmaceuticals (RYTM) raised $100 million in an initial public offering on Thursday, October 5th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen served as the underwriters for the IPO and Needham was co-manager. Who are Rhythm Pharmaceuticals' major shareholders? Rhythm Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (5.42%), Assenagon Asset Management S.A. (0.47%), Lord Abbett & CO. LLC (0.46%), Swiss National Bank (0.15%), Hennion & Walsh Asset Management Inc. (0.14%) and BNP Paribas Financial Markets (0.09%). Insiders that own company stock include Christopher Paul German, David P Meeker, Hunter C Smith, Jennifer Chien, Jennifer Kayden Lee, Joseph Shulman, Pamela J Cramer, William T Roberts and Yann Mazabraud. View institutional ownership trends. How do I buy shares of Rhythm Pharmaceuticals? Shares of RYTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RYTM) was last updated on 5/10/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsCharles Payne Demystifies OptionsUnstoppable ProsperityYou need to know these two things about AI stocks ASAP…InvestorPlaceShocking: One AI startup's revenue could surge 4,735%Manward PressMissed NVDA? Buy this AI stock NOWChaikin AnalyticsGold ManiaStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rhythm Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
